Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis

Baricitinib is an oral inhibitor of Janus kinases (JAKs), selective for JAK1 and 2. It demonstrated dose‐dependent efficacy in patients with moderate‐to‐severe rheumatoid arthritis (RA) in a phase IIb study up to 24 weeks. Population pharmacokinetic/pharmacodynamic (PopPK/PD) models were developed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Chua, Laiyi, Ernest, Charles, Macias, William, Rooney, Terence, Tham, Lai San
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744177/
https://www.ncbi.nlm.nih.gov/pubmed/28891251
http://dx.doi.org/10.1002/psp4.12251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744177/
https://www.ncbi.nlm.nih.gov/pubmed/28891251
http://dx.doi.org/10.1002/psp4.12251

Ejemplares similares